Results 21 to 30 of about 5,892 (166)

Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan [PDF]

, 2020
Background and objectives: Nephrolithiasis is a common health problem in autosomal dominant polycystic kidney disease (ADPKD) and significantly contributes to patient morbidity.
Bargagli, Matteo, Mariam Semmo, Fuster, Daniel G., Semmo, Mariam, Matteo Bargagli, Daniel G. Fuster, Anderegg, Manuel, Vogt, Bruno, Uyen Huynh-Do, Ferraro, Pietro Manuel, Huynh-Do, Uyen, Manuel Anderegg, Pietro Manuel Ferraro, Bruno Vogt, Dhayat, Nasser A., Nasser A. Dhayat   +15 more
core   +1 more source

The baseline demographic and laboratory data of the tolvaptan group and non-tolvaptan group.

, 2022
The baseline demographic and laboratory data of the tolvaptan group and non-tolvaptan group.
Akinari Sekine (4357189), Eiko Hasegawa (848440), Naoki Sawa (848442), Hiroki Mizuno (560647), Tatsuya Suwabe (848436), Masayuki Yamanouchi (848441), Junichi Hoshino (848432), Daisuke Ikuma (12102061), Yoshifumi Ubara (848444)   +8 more
core   +1 more source

Tolvaptan and urea in paediatric hyponatraemia [PDF]

, 2023
BACKGROUND: The syndrome of inappropriate antidiuretic hormone (SIADH) is usually treated with fluid restriction. This can be challenging in patients with obligate fluid intake for nutrition or medication. Pharmaceutical treatment with tolvaptan and urea
Amin, Rakesh, Alexandrou, Demitra, Gan, Hoong-Wei, Veligratli, Faidra, Bockenhauer, Detlef, Famuboni, Adeola, Lopez-Garcia, Camilo, Dattani, Mehul, Trompeter, Richard, Shah, Sarit   +9 more
core   +1 more source

Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?

Kidney Diseases, 2021
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder, accounting for approximately 5% of all ESRD cases worldwide.
Fei Liu, Chunyue Feng, Huijun Shen, Huaidong Fu, Jianhua Mao   +4 more
doaj   +1 more source

The safety and efficacy of tolvaptan in the treatment of patients with autosomal dominant polycystic kidney disease: A systematic review and meta-analysis

Nefrología (English Edition), 2023
Background: The irreversible progression of autosomal dominant polycystic kidney disease (ADPKD) to end-stage renal disease (ESRD) is delayed by tolvaptan.
Xuanwei Li, Wenlai Li, Yue Li, Chuanjiang Dong, Ping Zhu   +4 more
doaj   +3 more sources

Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations [PDF]

, 2018
Laia Sans-Atxer,1 Dominique Joly2 1Department of Nephrology, Hospital del Mar, Institut Mar for Medical Research, Barcelona, Spain; 2Faculty of Medicine, Université Paris-Descartes, Assistance Publique-Hôpitaux de Paris, Service de Né ...
Joly D, Dominique Joly, Sans-Atxer L, Sans Atxer, Laia, Laia Sans-Atxer, Joly, Dominique   +5 more
core   +1 more source

Can tolvaptan usage cause cytotoxicity? An in vitro study

, 2023
Objectives: Tolvaptan is a nonpeptide V2 (vasopressin) receptor antagonist which is commonly used for treatment of hypernatremia. Besides it is mostly used for rescue strategies of mutant V2 receptors which are responsible for congenital type of ...
TUNÇDEMİR, Beril ERDEM, Beril ERDEM TUNÇDEMİR   +1 more
core   +1 more source

10-Year Evaluation of Adherence and Satisfaction with Information about Tolvaptan in ADPKD: A Single-Center Pilot Study

Patient Preference and Adherence, 2021
Holger Schirutschke, Peter Gross, Alexander Paliege, Christian Hugo University Hospital Carl Gustav Carus at the Technische, Universität Dresden, Department of Internal Medicine III, Division of Nephrology, Dresden, GermanyCorrespondence: Holger ...
Schirutschke H, Gross P, Paliege A, Hugo C   +3 more
doaj  

Total body fluid is the factor that affects the pharmacokinetics of tolvaptan, and its efficacy, in acute worsening heart failure patients

Pharmacology Research & Perspectives, 2023
The optimal starting dose of tolvaptan to effectively improve fluid retention in patients with heart failure (HF) is unknown. This study explored the factors affecting the pharmacokinetics (PKs) and pharmacodynamics of tolvaptan in patients with ...
Takahiro Kato, Yoko Yasuda, Hitomi Okamoto, Yuji Saito, Yusuke Nakano, Katsuhiko Matsuura, Masafumi Oonishi, Tetsuya Amano   +7 more
doaj   +1 more source

Tolvaptan induces body fluid loss and subsequent water conservation in normal rats

Journal of Pharmacological Sciences, 2022
We have recently reported that the urea osmolyte-associated water conservation system is activated in fluid loss models such as high salt-induced natriuresis, renal injury-induced impaired renal concentrating ability, or skin barrier dysfunction-induced ...
Satoshi Kidoguchi, Kento Kitada, Yoshihide Fujisawa, Daisuke Nakano, Takashi Yokoo, Jens Titze, Akira Nishiyama   +6 more
doaj   +1 more source